Monday, March 31, 2014

Liberian health authorities confirm 2 cases of Ebola, WHO says - Fox News

The World Health Organization (WHO) said on Sunday that Liberia has confirmed two cases of the deadly Ebola virus that is suspected to have killed at least 70 people in Guinea.



The outbreak of the highly contagious Ebola, which in its more acute phase, causes vomiting, diarrhoea and external bleeding, has sent Guinea's West African neighbors scrambling to contain the spread of the disease.



Eleven deaths in towns in northern Sierra Leone and Liberia, which shares borders with southeastern Guinea where the outbreak was first reported, are suspected to be linked to Ebola.



WHO said that as of March 29, seven clinical samples from adult patients from Foya district in Liberia were tested.



"Two of those samples have tested positive for the ebolavirus," the global health organization said in the statement on its website on Sunday, confirming for the first time the cases in country.



"There have been 2 deaths among the suspected cases; a 35 year old woman who died on 21 March tested positive for ebolavirus while a male patient who died on 27 March tested negative," it said.



An official of Liberia's health ministry who requested anonymity said the government was aware and would issue a statement on Monday.



The suspected spread of disease into Liberia and Sierra Leone has stirred concern that one of the most lethal infectious diseases known to man could spread in a poor corner of West Africa, where health systems are ill-equipped to cope.



Authorities in Guinea's northwestern neighbor Senegal closed its land border on Saturday and suspended weekly markets near the borders where fresh produce from Guinea were sold in order to prevent the spread of the Ebola virus.



Sanitary checks have also been introduced on flights between Dakar and the Guinean capital Conakry. Regional airline Gambia Bird has also announced that it will delay the launch of services to Conakry, due to start on Sunday, because of the outbreak.



The World Health Organization said in the statement it does not recommend any travel or trade restrictions be applied to Liberia, Guinea or Sierra Leone based on the current information available about the outbreak.



Ebola has killed more than 1,500 people since it was first recorded in 1976 in what is now Democratic Republic of Congo, but this is the first fatal outbreak in West Africa.











via Smart Health Shop Forum http://ift.tt/1dKywZ7

Bayer gets EU approval for lung-disease drug - MarketWatch

By Neetha Mahadevan



FRANKFURT--Bayer AG (BAYN.XE) said Monday its pulmonary hypertension drug, Adempas, has been approved by the European Commission for the treatment of two chronic forms of hypertension, chalking up another approval for one of its five key drugs.



Adempas, also known as Riociguat, is one of Bayer's five promising new drugs with a combined sales potential of EUR7.5 billion. Adempas, which alone has peak sales potential of more than EUR500 million annually, is the first and only drug approved for patients with chronic thromboembolic pulmonary hypertension, or CTEPH. The drug has also been approved to treat patients with pulmonary arterial hypertension, or PAH.



"With the approval of Adempas by the European Commission, an important new treatment option becomes available for patients with pulmonary hypertension in Europe," Bayer HealthCare's Head of Global Development Joerg Moeller said.



Adempas has been approved in the U.S. and Canada for both forms of pulmonary hypertension, while it was approved in Japan for CTEPH in January this year. In the European Union, riociguat has also been granted orphan drug designation.



Pulmonary hypertension is a severe, life-threatening disorder of the heart and lungs in which the blood pressure in the pulmonary arteries is above normal, and which can lead to heart failure and death.



Write to Neetha Mahadevan at neetha.mahadevan@wsj.com



Subscribe to WSJ: http://ift.tt/N7NEw4











via Smart Health Shop Forum http://ift.tt/1hbPcDQ

FDA allows Curis to resume testing cancer drug - Reuters

Mon Mar 31, 2014 7:50am EDT





(Reuters) - Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial.



The company's shares jumped about 22 percent to $3.35 in trading before the bell.



Enrolment for the study was halted after the death of a patient with advanced breast cancer, who experienced acute liver failure about a month after the drug, codenamed CUDC-427, was discontinued.



The trial began in the third quarter of 2013 in patients with advanced solid tumors or lymphomas.



Curis said it planned to continue testing the drug - including in combination with chemotherapy drug, capecitabine - in patients of a type of advanced breast cancer.



The Lexington, Massachusetts-based company's shares closed at $2.75 on the Nasdaq on Friday.









via Smart Health Shop Forum http://ift.tt/1dKyvnZ

Good for the heart: Marriage leads to lower risk of heart disease - TheCelebrityCafe.com

Is it true that love heals all wounds? A new study shows that married couples have a lower risk of heart disease compared to those who are not married.



Researchers at New York University's Langone Medical Center studied more than 3.5 million people, and discovered that married couples experience less heart disease compared to those who are single, divorced, or widowed, reports Fox News.



Researchers studied both young and old patients, and made sure to screen for other factors that could negatively contribute to heart health, such as obesity and smoking.



The Associated Press notes that the researchers do not know how long couples have been married, or how long someone has been divorced or widowed.



The study is the largest of its kind and more extensive than those in the past. Plus, the findings could potentially change the idea that marriage is harmful to your health, as some previous studies have concluded.



Fox News reports that Dr. Carlos Alviar of NYU believes that a supportive partner is key to heart health. "People who have a spouse might be more compliant with medical appointments, screening processes, more compliant with medications and a healthy lifestyle as opposed to people who are by themselves," he said.



Interestingly, there might be some medical truth to the common "heartsick" or "brokenhearted" phrases used when a relationship ends in turmoil. “While people who were divorced had higher odds of any vascular disease, particularly aortic and cerebrovascular, people who were widowed had the highest odds for coronary and lower extremity disease,” Alviar said.











via Smart Health Shop Forum http://ift.tt/1hbP9rG

Bayer gets EU nod to widen use of lung drug Adempas

FRANKFURT Mon Mar 31, 2014 5:01am EDT




  • Tweet<li class="c4"/><li class="linkedIn" tns="no"/>

  • Share this

  • <span id="googleTag"/>

  • Email

  • Print


The logo of Bayer AG is pictured at the Bayer Healthcare subgroup production plant in Wuppertal February 24, 2014.



Credit: Reuters/Ina Fassbender







<span id="articleText"/>FRANKFURT (Reuters) - German drugmaker Bayer said on Monday it won approval in the European Union to widen the use of lung drug Adempas to two life-threatening forms of pulmonary hypertension.



<span id="midArticle_0"/>The EU Commission cleared the use of the drug, also known as riociguat, for the treatment of chronic-thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).



<span id="midArticle_1"/>U.S. authorities approved the drug for the same uses in October.



<span id="midArticle_2"/>Bayer counts Adempas among its most promising new drugs, predicting peak annual sales of more than 500 million euros ($688 million).



<span id="midArticle_3"/>($1 = 0.7271 Euros)



<span id="midArticle_4"/>(Reporting by Ludwig Burger; Editing by Christoph Steitz)



<span id="midArticle_5"/>

  • Tweet this

  • Link this

  • Share this

  • Digg this

  • Email

  • Print

  • Reprints


We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://ift.tt/NWKAHy

<a name="comments"/>Comments (0)



Be the first to comment on reuters.com.



Add yours using the box above.















via Smart Health Shop Forum http://ift.tt/1hbP8UG